Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | ABL2 | P42684 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GRN | P28799 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205964 | 0.89 | PRKCZ (0.57) | PRKCZMAPK14MAPK11ABL1ABL2 | |
| SCHEMBL13946380 | 0.87 | L3MBTL1 (0.49) | PRKCZMAPK14MAPK11ABL1ABL2 | |
| SCHEMBL10070684 | 0.84 | PRKCZ (0.49) | PRKCZMAPK14MAPK11CDK8DDR2 | |
| SCHEMBL368379 | 0.84 | MEN1 (0.48) | PRKCZMAPK14MAPK11CDK8MAPT | |
| Hydrochloric Acid SCHEMBL4074918 | 0.83 | MEN1 (0.50) | PRKCZMAPK14MAPK11CDK8MAPT | |
| SCHEMBL16279767 | 0.83 | PRKCZ (0.42) | PRKCZMAPK14MAPK11CDK8SRC | |
| SCHEMBL16284441 | 0.82 | PTGS2 (0.41) | PRKCZMAPK14MAPK11ABL1ABL2 | |
| Hydrochloric Acid SCHEMBL16279933 | 0.81 | PTGS2 (0.41) | PRKCZMAPK14MAPK11ABL1ABL2 | |
| SCHEMBL10363266 | 0.81 | RAB9A (0.49) | PRKCZMAPK14MAPK11CDK8MAPT | |
| SCHEMBL1283896 | 0.80 | CDK8 (0.47) | PRKCZMAPK14MAPK11CDK8MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788345-B1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2020-06-10 | — | — | EP | disclosed |
| EP-3004097-B1 | KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2018-01-17 | — | — | EP | disclosed |
| US-9458154-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-10-04 | — | — | US | disclosed |
| US-9458154-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-10-04 | — | — | US | disclosed |
| US-9440974-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-13 | — | — | US | disclosed |
| EP-3004097-A1 | KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2016-04-13 | — | — | EP | disclosed |
| US-20160016953-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A (IT) | 2016-01-21 | — | — | US | disclosed |
| US-9181242-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-20150057273-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-02-26 | — | — | US | disclosed |
| US-20150057273-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-02-26 | — | — | US | disclosed |
| US-20140364412-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | US | disclosed |
| WO-2014195402-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | WO | disclosed |
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PFIZER INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090012079-A1 | Triazolopyridine Compounds | LEWTHWAITE RUSSELL ANDREW | 2009-01-08 | — | — | US | disclosed |
| EP-1987022-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | Pfizer Products Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1984363-A1 | TRIAZOLOPYRIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007091152-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091152-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091176-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091176-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012079-A1 | Triazolopyridine Compounds | MAPKAPK5, MAPK1, MAPK4 | PRKCZ 643/4885MAPK14 26/4885MAPK11 54/4885 |
| US-20160016953-A1 | KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K6 | PRKCZ 378/4885MAPK14 33/4885MAPK11 44/4885 |
| US-20140364412-A1 | KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K6 | PRKCZ 378/4885MAPK14 33/4885MAPK11 44/4885 |
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PDXK, UMPS, CDK2 | PRKCZ 316/4885MAPK14 117/4885MAPK11 404/4885 |
| US-20150057273-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK4 | PRKCZ 552/4885MAPK14 27/4885MAPK11 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.